Current strategies for treatment of relapsed/refractory multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is a hematologic malignancy with a high relapse rate, despite treatment advances.
• Relapsed and refractory MM (RRMM) presents significant challenges due to disease progression and chemotherapy resistance.
• Salvage chemotherapy is essential for managing relapsed MM patients.

Purpose of the Study:

• To review current therapeutic strategies for RRMM.
• To highlight the role of novel pharmacologic agents and immunotherapies in RRMM treatment.
• To discuss emerging drug classes and their potential impact on patient outcomes.

Main Methods:

• Literature review of recent clinical trials and studies in RRMM.
• Analysis of treatment outcomes with immunomodulatory agents and proteasome inhibitors.
• Evaluation of novel drug classes including monoclonal antibodies and HDAC inhibitors.

Main Results:

• Combination regimens with immunomodulatory agents and proteasome inhibitors demonstrate encouraging response rates and duration.
• Newer agents like pomalidomide and carfilzomib are effective in RRMM.
• Novel drug classes, including oral proteasome inhibitors (ixazomib, oprozomib), monoclonal antibodies (elotuzumab, daratumumab), and HDAC inhibitors (panobinostat, rocilinostat), show promising activity.

Conclusions:

• Despite advances, MM remains incurable, underscoring the need for effective RRMM therapies.
• Immunomodulatory agents and proteasome inhibitors are foundational treatments for RRMM.
• Emerging novel agents offer new hope and improved therapeutic options for patients with relapsed and refractory multiple myeloma.